Abstract: N6-methyladenosine (m6A) has been identified as the most common epigenetic modification of eukaryote mRNA. It can not only mediate multiple processes of RNA metabolism such as RNA splicing, translation and decay under the catalytic regulation of m6A-related enzymes, but also affect the development of bone marrow hematopoiesisregulating the self-renewal, proliferation and differentiation of pluripotent stem cells in the hematopoietic microenvironment of bone marrow. In recent years, many studies have reported that m6A methylation modification plays an important role in the development and progression of hematological malignancies. Targeting inhibition of m6A-related factors contributes to increase the sensitivity of patients with hematological malignancies to therapeutic drugs. This review describes the biological characteristics and hematopoietic regulation mechanisms of m6A methylation modification, and its role in the pathogenesis of hematological malignancies.

Key words: N6-methyladenosine (m6A), hematologic neoplasm, methylation, gene , stem cell